Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ZAP70 | P43403 | 10/20 | 0.51 |
| ▸ | SYK | P43405 | 6/20 | 0.43 |
| ▸ | KHK | P50053 | 1/20 | 0.40 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.38 |
| ▸ | CDK4 | P11802 | 1/20 | 0.37 |
| ▸ | CCND1 | P24385 | 1/20 | 0.37 |
| ▸ | CCND2 | P30279 | 1/20 | 0.37 |
| ▸ | CCND3 | P30281 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1048401 | 0.87 | ZAP70 (0.48) | ZAP70SYK | |
| SCHEMBL1079980 | 0.81 | ZAP70 (0.44) | ZAP70ALK | |
| SCHEMBL27826692 | 0.81 | ZAP70 (0.42) | ZAP70SYK | |
| SCHEMBL1047678 | 0.80 | ZAP70 (0.48) | ZAP70 | |
| SCHEMBL1044404 | 0.80 | EGFR (0.40) | ZAP70SYK | |
| SCHEMBL1048544 | 0.79 | ZAP70 (0.39) | ZAP70SYK | |
| SCHEMBL3359622 | 0.79 | ALK (0.39) | SYKKHKALKCDK4CCND1 | |
| SCHEMBL1045987 | 0.78 | ZAP70 (0.52) | ZAP70SYK | |
| SCHEMBL1048756 | 0.77 | ZAP70 (0.41) | ZAP70SYK | |
| SCHEMBL27805889 | 0.77 | ALK (0.40) | SYKKHKALKCDK4CCND1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8546370-B2 | Compounds and compositions as kinase inhibitors | IRM LLC (BM) | 2013-10-01 | — | — | US | claimed |
| US-20110003798-A1 | COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS | IRM LLC (BM) | 2011-01-06 | — | — | US | claimed |
| US-8546370-B2 | Compounds and compositions as kinase inhibitors | IRM LLC (BM) | 2013-10-01 | — | — | US | disclosed |
| CN-101990539-A | Compounds and compositions as kinase inhibitors | IRM LLC | 2011-03-23 | — | — | CN | disclosed |
| US-20110003798-A1 | COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS | IRM LLC (BM) | 2011-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110003798-A1 | COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS | FYN, SYK, RET | ZAP70 4/4885SYK 2/4885KHK 2593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.